Greenwich LifeSciences, Inc. (GLSI) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$14.84

From 52W high−54.69%

Volume151914.00

Market cap$223.26M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$14.84

From 52W high

−54.69%

Volume

151914.00

Market cap

$223.26M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−9.9x

P/E (TTM)

—

RSI (14)

42.4

MomentumView details →

1D Return

+4.54%

YTD Return

−28.61%

SummaryUpdated Jun 1, 2026

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Stafford, Texas. Originally incorporated as Norwell, Inc., the company changed its name to Greenwich LifeSciences in March 2018 and went public in September 2020. The company focuses exclusively on developing novel cancer immunotherapies targeting breast cancer and other cancers that express the HER2/neu protein, with its lead product candidate GP2 having completed Phase IIb clinical trials.

Ask drillr about Greenwich LifeSciences, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−9.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

71.6x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−695.56%

ROA (TTM)

−244.25%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−13.24%

FCF YoY

−46.86%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−18.18%

EBITDA YoY

−23.63%

MomentumView details →

1D Return

+4.54%

YTD Return

−28.61%

1Y Return

+61.64%

RSI (14)

42.4

vs 50D SMA

−9.89%

vs 200D SMA

−31.40%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

1.54x

Quick Ratio

1.54x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.27

EPS Surprise

18.18%

Beats (12Q)

6/12

Next Q EPS Est

−$0.35

Avg Surprise (4Q)

−6.25%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−21.68M

Op. CF (TTM)

−12.49M

Next earningsNov 13, 2026 →

Latest newsMore news →

Greenwich LifeSciences received regulatory approval to expand its Phase III clinical trial FLAMINGO-01 into the United Kingdom.90d ago

Similar companies

Fate Therapeutics, Inc.FATE Larimar Therapeutics, Inc.LRMR Lexeo Therapeutics, Inc. Common StockLXEO Keros Therapeutics, Inc.KROS BridgeBio Oncology Therapeutics Inc.BBOT Zentalis Pharmaceuticals, Inc.ZNTL Find similar companies →

Latest newsMore news →

Greenwich LifeSciences' Board of Directors extended the lock-up of shares held by its directors, officers, and pre-IPO investors to January 31, 2027, restricting their sale of common stock until that date.71d ago Greenwich LifeSciences received regulatory approval to expand its Phase III clinical trial FLAMINGO-01 into the United Kingdom.90d ago